Daré Bioscience to Participate at the 33rd Annual Roth Conference
Daré Bioscience, Inc. (NASDAQ: DARE) announces that President and CEO Sabrina Martucci Johnson will participate in a panel on 'Women’s Health Companies Blazing the Trail' at the 33rd Annual Roth Conference from March 15-17, 2021. The panel discussion will highlight innovations in women's health. A webcast will be available on March 15, 2021, at 5:00 PM ET on their website, remaining accessible until March 29, 2021. Daré focuses on developing therapies for contraception, vaginal health, sexual health, and fertility.
- None.
- None.
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a panel discussion titled “Women’s Health Companies Blazing the Trail” at the 33rd Annual Roth Conference that will take place virtually March 15 – 17, 2021.
A webcast of the panel discussion will be available beginning March 15, 2021 at 5:00pm Eastern Time under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. The webcast will be available until March 29, 2021.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Contact:
Investors on behalf of Daré Bioscience, Inc.:
Tom Masterson
Allele Capital Partners
tmasterson@allelecapital.com
646.573.3216
Source: Daré Bioscience, Inc.
FAQ
What is the date of the 33rd Annual Roth Conference where Daré will be participating?
Who will represent Daré Bioscience in the panel discussion at the Roth Conference?
When can I access the webcast of Daré's panel discussion?
Until when can I view the webcast of Daré's panel discussion?
What are the main focus areas of Daré Bioscience?
What is DARE's ticker symbol on NASDAQ?
